Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and β2-microglobulin downregulation in breast cancer

Human Immunology

Volumn 70, Issue 7, 2009, Pages 492-495

  Morabito, Anna ^a   Dozin, Beatrice ^a   Salvi, Sandra ^a   Pasciucco, Gennaro ^a   Balbi, Giuseppe ^b   Laurent, Stefania ^a   Pastorino, Simona ^a   Carli, Franca ^a   Truini, Mauro ^a   Bruzzi, Paolo ^a   Del Mastro, Lucia ^a   Pistillo, Maria Pia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

2 Microglobulin; Breast cancer; Downregulation; HLA; Overall survival

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1;

ADULT; AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CELL; CANCER RADIOTHERAPY; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR NECROSIS;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS;

EID: 67449135854     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.04.029     Document Type: Article

References (25)

1. Goepel J.R., Rees R.C., Rogers K., Stoddard C.J., Thomas W.E., and Shepherd L. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 64 (1991) 880-883
2. Kaklamanis L., Leek R., Koukourakis M., Gatter K.C., and Harris A.L. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55 (1995) 5191-5194
3. Cabrera T., Angustias Fernandez M., Sierra A., Garrido A., Herruzo A., Escobedo A., et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50 (1996) 127-134
4. Vitale M., Rezzani R., Rodella L., Zauli G., Grigolato P., Cadei M., et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) downregulation in high-grade primary breast carcinoma lesions. Cancer Res 58 (1998) 737-742
5. Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1197;18:89-95.
6. Cabrera T., López-Nevot M.A., Gaforio J.J., Ruiz-Cabello F., and Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52 (2003) 1-9
7. York I.A., and Rock K.L. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14 (1996) 369-396
8. Redondo M., García J., Villar E., Rodrigo I., Perea-Milla E., and Serrano A. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 34 (2003) 1283-1289
9. Gudmundsdóttir I., Gunnlaugur Jónasson J., Sigurdsson H., Olafsdóttir K., Tryggvadóttir L., and Ogmundsdóttir H.M. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer 89 (2000) 500-505
10. Pistillo M.P., Nicolò G., Salvi S., Capanni P., Perdelli L., Pasciucco G., et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol 61 (2000) 397-407
11. Palmisano G.L., Pistillo M.P., Fardin P., Capanni P., Nicolò G., Salvi S., et al. Analysis of HLA-G expression in breast cancer tissues. Hum Immunol 63 (2002) 969-976
12. Palmisano G.L., Pistillo M.P., Capanni P., Pera C., Nicolò G., Salvi S., et al. Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immunol 62 (2001) 133-139
13. Garrido F., Cabrera T., Accolla R.S., Bensa J.C., Bodmer W., Dohr G., et al. HLA and cancer: 12th International Histocompatibility Workshop study. Genetic diversity of HLA functional and medical implications. In: Charron D. (Ed). Histocompatibility 1997 (1997), Medical and Scientific International Publisher, Paris
14. Hasebe T., Imoto S., Yokose T., Ishii G., Iwasaki M., and Wada N. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 39 (2008) 681-693
15. Mohammed R.A., Martin S.G., Gill M.S., Green A.R., Paish E.C., and Ellis I.O. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 31 (2007) 1825-1833
16. Pedersen L.O., Hansen A.S., Olsen A.C., Gerwien J., Nissen M.H., and Buus S. The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen. Scand J Immunol 39 (1994) 64-72
17. Vitiello A., Potter T.A., and Sherman L.A. The role of beta 2-microglobulin in peptide binding by class I molecules. Science 250 (1990) 1423-1426
18. Rowley D.R., Dang T.D., McBride L., Gerdes M.J., Lu B., and Larsen M. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res 55 (1995) 781-786
19. Nomura T., Huang W.C., Zhau H.E., Wu D., Xie Z., Mimata H., et al. Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res 12 (2006) 7294-7305
20. Wang M., Corlin D.B., Heegaard N.H., Claesson M.H., and Nissen M.H. Cellular expression or binding of desLys58-beta2 microglobulin is not dependent on the presence of the tri-molecular MHC class I complex. Scand J Immunol 67 (2008) 105-112
21. Klein T., Levin I., Niska A., Koren R., Gal R., Schachter J., et al. Correlation between tumour and serum beta 2m expression in patients with breast cancer. Eur J Immunogenet 23 (1996) 417-423
22. Concha A., Cabrera T., Ruiz-Cabello F., and Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. Int J Cancer Suppl 6 (1991) 146-154
23. Madjd Z., Spendlove I., Pinder S.E., Ellis I.O., and Durrant L.G. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117 (2005) 248-255
24. Ericsson C., Seregard S., Bartolazzi A., Levitskaya E., Ferrone S., Kiessling R., et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 42 (2001) 2153-2156
25. Menon A.G., Morreau H., Tollenaar R.A., Alphenaar E., Van Puijenbroek M., Putter H., et al. Downregulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 82 (2002) 1725-1733